Glucagonlike peptide-1 receptor agonist use was found to be associated with an increased risk of acute asthma exacerbations in adolescents with obesity.
Does glucagonlike peptide-1 receptor agonist use reduce acute asthma exacerbations in adolescents with overweight or obesity and asthma?
Absolute Event Rate: 0% vs 0%
This cohort study investigates the association between glucagonlike peptide-1 receptor agonist use and the risk of acute asthma exacerbations among adolescents with overweight or obesity and asthma.
Huang et al. (Mon,) reported a other. Glucagonlike peptide-1 receptor agonist use was found to be associated with an increased risk of acute asthma exacerbations in adolescents with obesity.